ClinicalTrials.gg
Active, not recruitingNCT01623076Updated Jan 6, 2026

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

An observational study in Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder and Transverse Myelitis, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by University of Texas Southwestern Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
6 Years and older
Sex
All
01

Study summary

This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand what happens biologically, preceding relapses. Gathering these data and samples will allow researchers to identify new ways of diagnosing and treating these diseases. Data and samples will be shared with researchers around the world to support collaborative efforts to treat these conditions.

Read the detailed description

This study seeks to determine the biologic causes of inflammation in patients with Neuromyelitis Optica (NMO), Transverse Myelitis (TM), optic neuritis (ON), related conditions and healthy controls. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand what happens biologically, preceding relapses. Gathering these data and samples will allow researchers to identify new ways of diagnosing and treating these diseases. Data and samples will be shared with researchers around the world to support collaborative efforts to treat these conditions.

Patients will agree to share medical records, complete questionnaires and donate samples on a timed basis.

02

Conditions studied

  • Neuromyelitis Optica
  • Neuromyelitis Optica Spectrum Disorder
  • Transverse Myelitis
  • Optic Neuritis

Keywords

  • Neuromyelitis Optica
  • Neuromyelitis Optica Spectrum Disorder
  • Transverse Myelitis
  • Optic Neuritis
  • Biorepository
03

In context

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

This study's planned enrollment of 150 is below the median of 200 across 62 observational studies indexed under Neuromyelitis Optica.

Browse Neuromyelitis Optica studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,010 studies on the registry; 199 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients previously diagnosed with Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis and Optic Neuritis will be recruited to take part in a longitudinal study of their disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6 years or greater
  • Male or Female
  • Patient or Parent (in the case of a minor) able to give
  • For patients 10 to 17, patient able to assent
  • Patient diagnosed with NMO, NMOSD, TM or ON

Exclusion criteria

Exclusion Criteria:

  • Unable to maintain scheduled visits
  • Patient has known or infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Neuromyelitis Optica Spectrum Disorder

    Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included

  • Transverse Myelitis and Optic Neuritis

    Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.

  • Healthy Controls

    patients without a history of CNS inflammation

  • Neuromyelitis Optica

    patients diagnosed with NMO

06

What researchers measure

Primary outcomes

  1. Measure change in standard clinical assessments over time

    Standard clinical assessments include: relapse information, level of disability based on EDSS score, high and low contract visual acuity, ambulation index, optical coherence tomography, and MRI, and neurologic/physical exam

    Time frame: Every study visit

Secondary outcomes

  1. Measure change in cognition measures over time

    Cognition measures include the SDMT, JLO, and PASAT

    Time frame: Every study visit

  2. Measure change in self-reported quality of life surveys

    Surveys include MSNQ, MSQOL-54, QIDS, BDI-II, FSS, ESS, MFIS, BPI, and Neuro-QoL

    Time frame: Every study visit

  3. B cell population changes

    Measure B cell subtypes and changes over time

    Time frame: Up to 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified data can be shared with IRB approved researchers upon request and approval from PI

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01623076
Responsible party
Benjamin Greenberg (Director, Neuromyelitis Optica and Transverse Myelitis Program, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jun 19, 2012
Start date
Jun 2012
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jan 6, 2026

Study contacts

Benjamin M Greenberg, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion